Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- Gloucester Pharmaceuticals To Present New Data From Two Studies On Romidepsin At ASCO
- Charities Launch Groundbreaking Research Cancer Centre In Newcastle, England
- Scientists Reveal 'Protector' Gene Behind 50-fold Increase In Number Of Bowel Tumours
- DDW: Better Polyp Detection with Deep Sedation (CME/CE)
- Protecting Healthy Cells From Radiation Damage
- ASTRO: Stereotactic Radiation Halts Spread of Lung CA (CME/CE)
- Researchers Find Clues To Improve Breast Cancer Survival
- $6.5 Million Gift To UCSF From Irwin And Joan Jacobs For Head And Neck Cancer Research
- Leading Scientist Professor Alan Ashworth To Receive Prestigious Award For Cancer Discoveries
- KCA: VEGF Inhibitor Shows Promise in Refractory RCC (CME/CE)
Prescription Cancer Drugs
Patient Response To Therapy For Gastrointestinal Stromal Tumors May Be Predicted By Gene Signature
Posted by: admin in Cancer Treatment, Prescription Cancer Drugs on May 19th, 2009
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
Lori Rink, PhD, a postdoctoral fellow in the laboratory of Andrew K. Godwin, PhD, at Fox Chase, presents their findings at the 2009 Annual Meeting of the American Society of Clinical Oncology. The study uses tumor specimens collected as part of a Phase II trial on the use of the drug before surgical resection for GIST, which is led by the Radiation Therapy Oncology Group, a national clinical cooperative group funded by the National Cancer Institute.
“Imatinib has been the first drug that has really made a dent in GIST progression - up to 80 percent response - yet some GIST patients have little or no response to the drug,” says Rink. “We are looking to see how we can help clinicians make better decisions in applying imatinib or additional therapies to their GIST patients.”
Rink and her colleagues followed 63 GIST patients in the RTOG trial, who were given imatinib before surgery for primary or recurrent tumors. Using tumor samples collected before and after the patients were given the drug, the researchers studied which genes were active in the tumors and then compared these profiles of gene expression to how well the tumors responded to short-term imatinib treatment.
According to Rink, they found a selection of 38 genes that were expressed higher in tumors that did not respond well to imatinib. Of these, they identified 20 KRAB-zinc finger genes that encode for proteins that typically act as transcriptional repressors of other genes. Ten of these genes, Rink says, are located to a single section of Chromosome 19.
“Our data indicate that if we can alter the activity of some of these KRAB-zinc finger proteins, we may be able to enhance the effectiveness of imatinib therapy,” Rink says.
Funding for this study comes from the National Cancer Institute, the Radiation Therapy Oncology Group Foundation and the GIST Cancer Research Fund.
Abstract #10533:
Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132.
Poster Discussion, Saturday, May 30
2:00 p.m.-6:00 p.m. - Level 2, W240A
5:00 p.m.-6:00 p.m. - Level 2, West Hall F5
Source:
Diana Quattrone
Fox Chase Cancer Center
View drug information on Gleevec.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.